Xeltis RestoreX - Model ETR - Endogenous Tissue Restoration Technology
Endogenous Tissue Restoration (ETR) is a new therapeutic approach, enabling the patient’s own body to naturally restore a new blood vessel or heart valve. With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ device, forming a new, natural and fully functional blood vessel or heart valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body. ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.
Technology safety
Xeltis’ restorative technology has been used for over 60 patient/years across cardiovascular applications to date
Reduced intervention
Xeltis’ cardiovascular devices may help reduce the need for repeated replacement procedures, invasive vessel harvesting or long-term medication
Growth potential
New, living devices developed with patient’s own tissue have the potential to grow as patients grow-up. Long-term clinical data will further provide supporting evidence
Low infection
Xeltis’ restorative devices may help reduce infection rates from recurrent operations, vein harvesting surgery or devices permanently implanted in the body
Availability
Xeltis’ implants are off-the-shelf devices made of polymers and ready to use. The devices do not depend on animal tissue or human tissue supplies
Cost-effectiveness
Xeltis’ restorative devices may help reduce the overall cost of blood vessel and heart valve replacement